Real-world data on the prevalence of BRCA1/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer
World Journal of Urology · 2024
DOI: 10.1007/s00345-024-05188-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Urology, 2024. Verfasst von Moritz Hommerding und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, University Hospital Bonn (UKB), Venusberg-Campus 1, Bonn, 53127, Germany. Hauptthemen laut MEDLINE: BRCA1 Protein, BRCA2 Protein, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Bonn.
Abstract (Originalsprache)
Purpose
This study seeks to contribute real-world data on the prevalence of BRCA1/2 and HRR gene mutations in prostate cancer.
Methods
We compiled sequencing data of 197 cases of primary and metastatic prostate cancer, in which HRR mutation analysis was performed upon clinical request within the last 5 years. All cases were analyzed using a targeted NGS BRCAness multigene panel, including 8 HRR genes (ATM, BRCA1, BRCA2, CDK12, CHEK2, FANCA, HDAC2, PALB2).
Results
Our findings reveal a prevalence of potentially targetable mutations based on FDA criteria of 20.8%, which is comparable to the literature. However, the frequency of targetable BRCA2 mutations within our cohort was lower than reported for mCRPC and ATM and CHEK2 mutations were more prevalent instead. Thus, while 20.8% ( n = 38) of the cases meet the criteria for olaparib treatment per FDA approval, only 4.9% ( n = 9) align with the eligibility criteria according to the EMA approval.
Conclusion
This study offers valuable real-world insights into the landscape of BRCA1/2 and HRR gene mutations and the practical clinical management of HRR gene testing in prostate cancer, contributing to a better understanding of patient eligibility for PARPi treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, University Hospital Bonn (UKB), Venusberg-Campus 1, Bonn, 53127, Germany.
- Department of Urology, Johanniter-Kliniken Bonn, Bonn, Germany.
- Department of Urology, University Hospital Bonn, Bonn, Germany.
- Institute of Pathology, University Hospital Bonn (UKB), Venusberg-Campus 1, Bonn, 53127, Germany. glen.kristiansen@ukbonn.de.
Förderung
- Universitätsklinikum Bonn
Zitieren
APA
Hommerding, M., Hommerding, O., Bernhardt, M., Kreft, T., Sanders, C., Tischler, V., Basitta, P., Pelusi, N., Wulf, A. L., Ohlmann, C. H., Ellinger, J., Ritter, M., & Kristiansen, G. (2024). Real-world data on the prevalence of BRCA1/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer. World Journal of Urology. https://doi.org/10.1007/s00345-024-05188-7
Vancouver
Hommerding M, Hommerding O, Bernhardt M, Kreft T, Sanders C, Tischler V, et al. Real-world data on the prevalence of BRCA1/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer. World Journal of Urology. 2024. doi:10.1007/s00345-024-05188-7
BibTeX
@article{Hommerding2024,
author = {Hommerding, Moritz and Hommerding, Oliver and Bernhardt, Marit and Kreft, Tobias and Sanders, Christine and Tischler, Verena and Basitta, Patrick and Pelusi, Natalie and Wulf, Anna-Lena and Ohlmann, Carsten-Henning and Ellinger, Jörg and Ritter, Manuel and Kristiansen, Glen},
title = {Real-world data on the prevalence of BRCA1/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer},
journal = {World Journal of Urology},
year = {2024},
doi = {10.1007/s00345-024-05188-7}
}
EUVIMED